secwatch.observer — SEC 8-K summary
======================================

Issuer:     Medicus Pharma Ltd. (MDCX)
CIK:        0001997296
Form:       8-K
Filed at:   2025-04-28T23:59:59+00:00
Accession:  0001062993-25-008086
Event type: m_and_a
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Medicus Pharma (MDCX) to acquire Antev Ltd. in share exchange; up to $65M in milestones
--------------------------------------------------------------------------------

- Consideration: 2,666,600 Medicus shares (~19% stake) plus up to US$65M contingent on FDA Phase 2/NDA approvals.
- Antev's lead asset Teverelix is a next-generation GnRH antagonist targeting acute urinary retention recurrence and high-CV-risk prostate cancer.
- Combined market opportunity estimated at ~$6B annually ($2B AUR, $4B prostate cancer).
- Transaction expected to close by end of June 2025, subject to due diligence, definitive agreement, and regulatory approvals.
- Antev shares subject to 9-month staggered lock-up and 36-month voting rights in favor of Medicus management.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1997296/000106299325008086/0001062993-25-008086-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1997296/000106299325008086/form8k.htm
  HTML page:      https://secwatch.observer/filing/0001062993-25-008086

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer